Serum Concentration of VEGF and PDGF-AA in Patients with Active Thyroid Orbitopathy before and after Immunosuppressive Therapy

 

 Buy Article Permissions and Reprints

Abstract

Introduction: Thyroid orbitopathy (TO) is the most frequent extrathyroid manifestation of Graves’ disease. The aim of this study was to evaluate the serum concentration of Vascular Endothelial Growth Factor (VEGF), Plated-Derived Growth Factor-AA (PDGF-AA) in the blood of patients with active OT before and after immunosuppressive therapy.

Patients and Methods: The study was performed in group of 39 patients with clinically active TO (Group A) in euthyroid (n=18, Group A I) and hyperthyroid (n=21, Group A II) stage of Graves’ disease in moderate or severe stage of TO. Control group consist of 20 healthy age-matched control subjects. Concentration of studied proangiogenic factors in serum samples were measured by an enzyme linked immunosorbent assay (ELISA) before (group A) and after (group A1) intensive pulse methylprednisolone treatment and one month after the end of additional oral methylprednisolone treatment (Group A2).

Results: We have found significant increased serum levels of VEGF in patients with TO (reg­ardless to treatment) when compared with control group (542.4±328.1 pg/ml vs. 94.6±55.3 pg/ml, p=0.0002) and increased serum levels of ­PDGF-AA in patients before treatment (3 173.6±1 480.3 pg/ml) in comparison with controls (1 768.9±520.0 pg/ml) and patients after intensive pulse methyloprednisolone treatment (2 325.9±1 456.8 pg/ml). One month after the end of additional oral methylprednisolone treatment (Group A2) concentration of PDGF-AA still decreased and were was not significant difference with value in control group (1 853.1±795.4 vs. 1 769.9±520.0 pg/ml, p=0.99). Serum concentration of VEGF was still significantly higher compared with control. We have not observed difference in serum concentration of studied proangiogenic factors between patients in euthyroid or hyperthyroid stage of Graves’ disease.

Conclusions: Results of the present study confirm the fact that angiogenesis could play a role in pathogenesis of thyroid orbitopathy.

• References

• 1 Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 2012; 26: 273-279
  CrossrefPubMedGoogle Scholar
• 2 Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002; 12: 855-860
  Google Scholar
• 3 Wall JR, Lahooti RS. Pathogenesis of thyroid eye disease – does autoimmunity against the TSH receptor explain all cases?. Endokrynol Pol 2010; 61: 222-227
  PubMedGoogle Scholar
• 4 Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves’ ophthalmopathy. J Clin Endocrinol Metab 2003; 88: 4246-4250
  CrossrefPubMedGoogle Scholar
• 5 Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy. Thyroid 2008; 18: 953-958
  CrossrefPubMedGoogle Scholar
• 6 Khalilzadeh O, Anvari M, Momen-Heravi F et al. Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in Graves’ disease. Clin Exp Med 2010; 10: 123-128
  CrossrefPubMedGoogle Scholar
• 7 Myśliwiec J, Palyga I, Nikołajuk A et al. Serum interleukin-16 and RANTES during treatment of Graves’ orbitopathy with corticosteroids and teleradiotherapy. Endokrynol Pol 2012; 63: 92-96
  PubMedGoogle Scholar
• 8 Medina J, Arroyo AG, Sanchez-Madrid F et al. Angiogenesis in Chronic Inflammatory Liver Disease. Hepatol 2004; 39: 1185-1195
  CrossrefPubMedGoogle Scholar
• 9 Chaparro M, Sanz-Cameno P, Trapero-Marugan M et al. Mechanisms of angiogenesis in chronic inflammatory liver disease. Ann Hepatol 2007; 6: 208-213
  PubMedGoogle Scholar
• 10 Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660
  CrossrefPubMedGoogle Scholar
• 11 Goth MI, Hubina E, Raptis S et al. Physiological and pathological angiogenesis in the endocrine system. Microsc Res Tech 2003; 60: 98-106
  CrossrefPubMedGoogle Scholar
• 12 Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934
  PubMedGoogle Scholar
• 13 Perez-Lopez M, Sales-Sanz M, Robolleda G et al. Retrobulbar ocular blood flow changes after orbital decompression in Graves’ ophthalmopathy measured by color Doppler imaging. Invest Ophthalmol Vis Sci 2011; 52: 5612-5617
  CrossrefPubMedGoogle Scholar
• 14 Kajdaniuk D, Marek B, Borgiel-Marek H et al. Transforming growth factor beta1 (TGFbeta1) in physiology and pathology. Endokrynol Pol 2013; 64: 384-396
  CrossrefPubMedGoogle Scholar
• 15 Bartalena L, Baldeschi L, Dickinson AJ et al. Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Eur J Endocrinol 2008; 158: 273-285
  CrossrefPubMedGoogle Scholar
• 16 Król A, Koehler A, Nowak M et al. Radioactive iodine (RIA) treatment of hyperthyroidism is safe in patients with Graves’ orbitopathy – a prospective study. Endokrynol Pol 2014; 65: 40-45
  PubMedGoogle Scholar
• 17 Brown LF, Berse B, Jackman RW et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255-1262
  PubMedGoogle Scholar
• 18 Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727-4735
  PubMedGoogle Scholar
• 19 Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91
  CrossrefPubMedGoogle Scholar
• 20 Fukumura D, Xavier R, Sugiura T. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715-725
  CrossrefPubMedGoogle Scholar
• 21 Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676
  CrossrefPubMedGoogle Scholar
• 22 Kraft A, Weindel K, Ochs A et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999; 85: 178-187
  CrossrefPubMedGoogle Scholar
• 23 Fenton C, Patel A, Dinauer C et al. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000; 10: 349-357
  CrossrefPubMedGoogle Scholar
• 24 Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000; 166: 475-480
  CrossrefPubMedGoogle Scholar
• 25 Jebreel A, England J, Bedford K et al. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Path 2007; 88: 271-277
  CrossrefPubMedGoogle Scholar
• 26 Iitaka M, Miura S, Yamanaka K et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 1998; 83: 3908-3912
  CrossrefPubMedGoogle Scholar
• 27 Nagura S, Katoh R, Miyagi E et al. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Hum Pathol 2001; 32: 10-17
  CrossrefPubMedGoogle Scholar
• 28 Turner HE, Harris AL, Melmed S et al. Angiogenesis in endocrine tumors. Endocr Rev 2003; 24: 600-632
  CrossrefPubMedGoogle Scholar
• 29 Sato K, Yamazaki K, Shizume K et al. Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 1995; 96: 1295-1302
  CrossrefPubMedGoogle Scholar
• 30 Matos K, Manso PG, Marback E et al. Protein expression of VEGF, IGF-1 and FGF in retroocular connective tissues and clinical correlation in Graves’ ophthalmopathy. Arq Bras Oftalmol 2008; 71: 486-492
  CrossrefPubMedGoogle Scholar
• 31 Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866
  CrossrefPubMedGoogle Scholar
• 32 Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 255-273
  CrossrefPubMedGoogle Scholar
• 33 van Steensel L, Paridaens D, Schrijver B et al. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci 2009; 50: 3091-3098
  CrossrefPubMedGoogle Scholar
• 34 van Steensel L, Paridaens D, Dingjan GM et al. Platelet-Derived Growth Factor-BB: A Stimulus for Cytokine Production by Orbital Fibroblasts in Graves’ Ophthalmopathy. Invest Ophthalmol Vis Sci 2010; 51: 1002-1007
  CrossrefPubMedGoogle Scholar
• 35 van Steensel L, Hooijkaas H, Paridaens D et al. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves’ ophthalmopathy patients. J Clin Endocrinol Metab 2012; 97: 944-953
  CrossrefPubMedGoogle Scholar